Diagnosis and management of interstitial lung disease

The complex tasks of making a confident diagnosis of a specific form of interstitial lung disease (ILD) and formulating a patient-centered, personalized management plan in an attempt to achieve remission or stabilization of the disease process can pose formidable challenges to clinicians. When patients are evaluated for suspected ILD, an accurate diagnosis of the specific form of ILD that a patient has developed must be made to provide the patient with useful prognostic information and to formulate an appropriate management plan that can relieve symptoms and restore or significantly improve quality of life. A well-performed patient history and physical examination provides invaluable information that can be combined with appropriate laboratory testing, imaging, and, if needed, tissue biopsy to reach a confident ILD diagnosis, and high-resolution computed tomography (HRCT) of the thorax is usually a key component of the diagnostic evaluation. If treatment is indicated, many forms of ILD can respond significantly to immunosuppressive anti-inflammatory therapies. However, ILD accompanied by extensive fibrosis may be difficult to treat, and the identification of an effective pharmacologic therapy for idiopathic pulmonary fibrosis (IPF) has remained elusive despite the completion of many phase 3 clinical trials over the past decade. Nonetheless, patients with IPF or advanced forms of non-IPF ILD can benefit significantly from detection and treatment of various co-morbid conditions that are often found in patients (especially the elderly patient), and supportive care (oxygen therapy, pulmonary rehabilitation) can have a beneficial impact on quality of life and symptom palliation. Finally, lung transplantation is an option for patients with progressive, advanced disease that does not respond to other therapies, but only a relatively small subset of patients with end-stage ILD are able to meet wait listing requirements and eventually undergo successful lung transplantation.

[1]  E. Savarino,et al.  Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. , 2009, American journal of respiratory and critical care medicine.

[2]  G. Raghu,et al.  Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? , 2012, European Respiratory Journal.

[3]  I. Noth,et al.  Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. , 2011, Arquivos de gastroenterologia.

[4]  K. Brown,et al.  Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease , 2011, European Respiratory Journal.

[5]  David A Lynch,et al.  High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. , 2005, American journal of respiratory and critical care medicine.

[6]  A. Wells,et al.  Acute Exacerbations of Idiopathic Pulmonary Fibrosis , 2013, Respiration.

[7]  K. Anstrom,et al.  Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. , 2013, Chest.

[8]  S. Sahn,et al.  Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[9]  Joyce S Lee,et al.  Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[10]  M. Glassberg,et al.  Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. , 2013, American journal of respiratory and critical care medicine.

[11]  Sang-Do Lee,et al.  Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[12]  K. Anstrom,et al.  A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[13]  Susan Murray,et al.  Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? , 2004, American journal of respiratory and critical care medicine.

[14]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[15]  A. Wells,et al.  The evolving pharmacotherapy of pulmonary fibrosis , 2013, Expert opinion on pharmacotherapy.

[16]  C. Strange,et al.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. , 2012, Chest.

[17]  G. Hunninghake,et al.  Idiopathic pulmonary fibrosis. , 2001, The New England journal of medicine.

[18]  T. Maher,et al.  Current and novel drug therapies for idiopathic pulmonary fibrosis , 2012, Drug design, development and therapy.

[19]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[20]  S. Kimmel,et al.  Association between pulmonary fibrosis and coronary artery disease. , 2004, Archives of internal medicine.

[21]  K. Meyer,et al.  Interstitial lung disease in the elderly: pathogenesis, diagnosis and management. , 2011, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[22]  Johny Verschakelen,et al.  High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[23]  H. Collard,et al.  Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis , 2011, European Respiratory Journal.

[24]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  H. Collard,et al.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[26]  Luca Richeldi,et al.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[27]  S. Rosselot Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[28]  Charlie Strange,et al.  An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. , 2012, American journal of respiratory and critical care medicine.

[29]  S. Nathan,et al.  Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases , 2013, Current opinion in pulmonary medicine.

[30]  G. Raghu,et al.  GER and Aspiration in Interstitial Lung Disease , 2012 .

[31]  N. Kaminski,et al.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[32]  H. Collard,et al.  Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[33]  K. Meyer,et al.  Review: Therapies for interstitial lung disease: past, present and future , 2008, Therapeutic advances in respiratory disease.

[34]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[35]  T. Pincus,et al.  Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. , 2010, Respiratory medicine.

[36]  N. Todd,et al.  Molecular and cellular mechanisms of pulmonary fibrosis , 2012, Fibrogenesis & tissue repair.

[37]  Joyce S Lee,et al.  Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis , 2012, Thorax.

[38]  C. Ruppert,et al.  Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis , 2012, European Respiratory Review.

[39]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.

[40]  S. Nathan,et al.  Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. , 2010, Respiratory medicine.

[41]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[42]  F. Martinez,et al.  Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[43]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[44]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[45]  R. Cornwell,et al.  Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation. , 2012, Interactive cardiovascular and thoracic surgery.

[46]  H. Collard,et al.  Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. , 2009, Chest.

[47]  K. Chida,et al.  Cumulative incidence of and predictive factors for lung cancer in IPF , 2009, Respirology.

[48]  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). , 2000, American journal of respiratory and critical care medicine.

[49]  G. Raghu,et al.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. , 2005, Chest.

[50]  T. Johkoh,et al.  Acute exacerbation of interstitial pneumonia following surgical lung biopsy. , 2006, Respiratory medicine.

[51]  H. Collard,et al.  Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials , 2013, Respiratory Research.

[52]  H. Collard,et al.  Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. , 2012, American journal of respiratory and critical care medicine.

[53]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[54]  E. Savarino,et al.  Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients , 2013, European Respiratory Journal.

[55]  C. Pellegrini,et al.  Typical GERD symptoms and esophageal pH monitoring are not enough to diagnose pharyngeal reflux. , 2005, The Journal of surgical research.

[56]  Keith McNeil,et al.  International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT). , 1998, American journal of respiratory and critical care medicine.

[57]  G. Raghu,et al.  Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? , 2011, European Respiratory Journal.

[58]  Moisés Selman,et al.  Idiopathic pulmonary fibrosis , 2011, The Lancet.

[59]  D. Fairclough,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2010 .

[60]  K. Meyer,et al.  Immunosuppressive therapy for autoimmune lung diseases. , 2012, Immunology and allergy clinics of North America.

[61]  S. Sahn,et al.  Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[62]  K. Meyer,et al.  Optimizing post-transplant outcomes in lung transplantation , 2008, Expert review of respiratory medicine.

[63]  M. Tamm,et al.  Diagnostic yield of flexible bronchoscopy in current clinical practice. , 2006, Swiss medical weekly.

[64]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[65]  H. Date,et al.  [Lung transplantation]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[66]  D. S. Kim Acute exacerbations in patients with idiopathic pulmonary fibrosis , 2013, Respiratory Research.

[67]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[68]  K. Meyer,et al.  Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy. , 2013, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[69]  K. Anstrom,et al.  The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. , 2012, Respiratory medicine.

[70]  T. Colby,et al.  Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. , 2013, Chest.

[71]  David P. Naidich,et al.  Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature. , 2013, American journal of respiratory and critical care medicine.

[72]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality , 2011, European Radiology.

[73]  O. Hilberg,et al.  Idiopathic Pulmonary Fibrosis - Diagnosis and Treatment , 2014 .

[74]  D. Schroeder,et al.  High short-term mortality following lung biopsy for usual interstitial pneumonia. , 2001, The European respiratory journal.

[75]  R. D. du Bois,et al.  Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease , 2013, The Journal of Rheumatology.

[76]  J. Kanne Interstitial lung disease (ILD): imaging finding, and the role of imaging in evaluating the patient with known or suspected ILD. , 2010, Seminars in roentgenology.

[77]  F. Martinez,et al.  International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[78]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.

[79]  S. Palmer,et al.  Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. , 2011, Chest.

[80]  F. Martinez,et al.  Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema , 2010, European Respiratory Journal.

[81]  L. Rose,et al.  Patient evaluation. , 1987, Dental clinics of North America.

[82]  A. Oikonomou,et al.  A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis , 2013, Journal of Translational Medicine.